Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation often initially respond to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment but may acquire drug resistance due to multiple factors. MicroRNAs are a class of small noncoding and endoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fengfeng, Meng, Fei, Wong, Sze Chuen Cesar, Cho, William C.S., Yang, Sijun, Chan, Lawrence W.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303773/
https://www.ncbi.nlm.nih.gov/pubmed/32552611
http://dx.doi.org/10.1177/1753466620915156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303773/
https://www.ncbi.nlm.nih.gov/pubmed/32552611
http://dx.doi.org/10.1177/1753466620915156

Ejemplares similares